 | 
|
 Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy April 14, 2008 Motor Neuron Disease is Leading Cause of Death for Infants Genzyme Genetics, a business unit of Genzyme Corporation (NASDAQ: GENZ), announced today that it is the first national laboratory specializing in reproductive testing to provide population carrier and prenatal diagnostic testing for spinal muscular atrophy (SMA), the most common inherited cause of infant mortality. more  Population-based Carrier Screening for Single Gene Disorders: Lessons Learned and New Opportunities March 2008 The National Human Genome Research Institute (NHGRI) and the National Institute of Child Health and Human Development (NICHD) jointly sponsored a workshop in February 2008 to examine carrier screening policy featuring SMA as an exemplar disease. This workshop represents the first federally sponsored formal review of carrier screening policy in 11 years. Please click on the link to view the introduction, summary of presentations, reports from small groups and concluding remarks from this presentation. more |
 |
